
STERIS plc: shareholders and insiders
Price
$261.91
November 16, 2026Market cap $25.6B
What Ploutos Investor adds for STERIS
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from FY2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 16, 2025 to Nov 12, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$8.6M
8 people
From Nov 16, 2025 to Nov 16, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan14%
- The rest86%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 16, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $6.0M by 6 people
- 2025: no buys, sold $2.6M by 2 people
- 2026: no buys, sold $6.0M by 6 people
- Nov 11, 2026Karen L BurtonSr. Vice Pres., CFOKind
- Nov 11, 2026Karen L BurtonSr. Vice Pres., CFOKind
- Nov 10, 2026Mohsen SohiDirectorKind
- Nov 10, 2026Mohsen SohiDirectorKind
- Nov 10, 2026Mohsen SohiDirectorKind
- Oct 1, 2026Karen L BurtonSr. Vice Pres., CFOKind
- Aug 12, 2026Mohsen SohiDirectorKind
- Aug 12, 2026Mohsen SohiDirectorKind
- Jul 1, 2026Mohsen SohiDirectorKind
- Jul 1, 2026Mohsen SohiDirectorKind
- Jun 15, 2026John Adam ZangerleSr. VP, Gen Counsel, and Sec.Kind10b5-1
- Jun 5, 2026Daniel A CarestioPresident and CEOKind10b5-1
- Jun 4, 2026John Adam ZangerleSr. VP, Gen Counsel, and Sec.Kind
- Jun 4, 2026Renato TamaroV.P. & Corporate TreasurerKind
- Jun 4, 2026Julia MadsenSr. VP and GM, Life SciencesKind
- Jun 4, 2026Kenneth E KohlerSVP & GM, ASTKind
- Jun 4, 2026Mary Clare FraserSVP & Chief HROKind
- Jun 4, 2026Daniel A CarestioPresident and CEOKind10b5-1
- Jun 4, 2026Daniel A CarestioPresident and CEOKind10b5-1
- Jun 4, 2026Karen L BurtonSr. Vice Pres., CFOKind
- Jun 3, 2026John Adam ZangerleSr. VP, Gen Counsel, and Sec.Kind
- Jun 3, 2026Renato TamaroV.P. & Corporate TreasurerKind
- Jun 3, 2026Julia MadsenSr. VP and GM, Life SciencesKind
- Jun 3, 2026Kenneth E KohlerSVP & GM, ASTKind
- Jun 3, 2026Mary Clare FraserSVP & Chief HROKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Karen L BurtonSr. Vice Pres., CFO | 5,880 | $147.05 | $864.7K | Form 4 | |
| Nov 11, 2026 | Karen L BurtonSr. Vice Pres., CFO | 5,880 | $255.62 | $1.5M | Form 4 | |
| Nov 10, 2026 | Mohsen SohiDirector | 4,893 | $114.74 | $561.4K | Form 4 | |
| Nov 10, 2026 | Mohsen SohiDirector | 3,228 | $252.87 | $816.3K | Form 4 | |
| Nov 10, 2026 | Mohsen SohiDirector | 1,665 | $253.90 | $422.7K | Form 4 | |
| Oct 1, 2026 | Karen L BurtonSr. Vice Pres., CFO | 228 | – | – | Form 4 | |
| Aug 12, 2026 | Mohsen SohiDirector | 4,058 | $86.23 | $349.9K | Form 4 | |
| Aug 12, 2026 | Mohsen SohiDirector | 4,058 | $235.78 | $956.8K | Form 4 | |
| Jul 1, 2026 | Mohsen SohiDirector | 3,781 | $71.40 | $270.0K | Form 4 | |
| Jul 1, 2026 | Mohsen SohiDirector | 1,837 | $212.30 | $390.0K | Form 4 | |
| Jun 15, 2026 | John Adam ZangerleSr. VP, Gen Counsel, and Sec. | 10b5-1 | 1,419 | $209.28 | $297.0K | Form 4 |
| Jun 5, 2026 | Daniel A CarestioPresident and CEO | 10b5-1 | 1,374 | $212.00 | $291.3K | Form 4 |
| Jun 4, 2026 | John Adam ZangerleSr. VP, Gen Counsel, and Sec. | 401 | $212.24 | $85.1K | Form 4 | |
| Jun 4, 2026 | Renato TamaroV.P. & Corporate Treasurer | 65 | $212.24 | $13.8K | Form 4 | |
| Jun 4, 2026 | Julia MadsenSr. VP and GM, Life Sciences | 195 | $212.24 | $41.4K | Form 4 | |
| Jun 4, 2026 | Kenneth E KohlerSVP & GM, AST | 150 | $212.24 | $31.8K | Form 4 | |
| Jun 4, 2026 | Mary Clare FraserSVP & Chief HRO | 600 | $212.24 | $127.3K | Form 4 | |
| Jun 4, 2026 | Daniel A CarestioPresident and CEO | 10b5-1 | 1,889 | $212.24 | $400.9K | Form 4 |
| Jun 4, 2026 | Daniel A CarestioPresident and CEO | 10b5-1 | 3,054 | $214.64 | $655.5K | Form 4 |
| Jun 4, 2026 | Karen L BurtonSr. Vice Pres., CFO | 90 | $212.24 | $19.1K | Form 4 | |
| Jun 3, 2026 | John Adam ZangerleSr. VP, Gen Counsel, and Sec. | 365 | $210.19 | $76.7K | Form 4 | |
| Jun 3, 2026 | Renato TamaroV.P. & Corporate Treasurer | 64 | $210.19 | $13.5K | Form 4 | |
| Jun 3, 2026 | Julia MadsenSr. VP and GM, Life Sciences | 239 | $210.19 | $50.2K | Form 4 | |
| Jun 3, 2026 | Kenneth E KohlerSVP & GM, AST | 184 | $210.19 | $38.7K | Form 4 | |
| Jun 3, 2026 | Mary Clare FraserSVP & Chief HRO | 311 | $210.19 | $65.4K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by STE's officers and directors from 2019 up to November 15, 2025, 7 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 2 more, back to 2019
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Vanguard Capital ManagementShare of class7.48%
- State StreetShare of class5.10%
- Vanguard Portfolio ManagementShare of class5.05%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Vanguard Capital Management | 7.48% | 7.34M | Apr 30, 2026 | 13G | |
| State Street | 5.10% | 5.00M | May 12, 2026 | 13G | |
| Vanguard Portfolio Management | 5.05% | 4.96M | Apr 29, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- AQR CapitalIn the quarter+30%
- D.E. ShawIn the quarter+189%
- Citadel Advisors (Griffin)In the quarter+268%
- Renaissance TechnologiesIn the quarter+27%
- Millennium Mgmt (Englander)In the quarter+803%
- Bridgewater (Dalio)In the quarter-12%
- Point72 (Cohen)In the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| AQR Capital | 1.38M | +30% | $286M | 0.10% |
| D.E. Shaw | 509.6K | +189% | $107M | 0.07% |
| Citadel Advisors (Griffin) | 404.3K | +268% | $85M | 0.05% |
| Renaissance Technologies | 147.1K | +27% | $31M | 0.04% |
| Millennium Mgmt (Englander) | 229.1K | +803% | $48M | 0.03% |
| Bridgewater (Dalio) | 9,809 | -12% | $2.1M | 0.01% |
| Point72 (Cohen) | – | – | 0.01% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 2.46% of its shares outstanding were held short, -16.1% since the report before.
- Shares held short
- 2.40M
- 2.46%
- Since the report before2.86M on Sep 30, 2026
- -16.1%
- 3.6
- 672.8K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 42%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 1.20M
- Nov 15, 2023: Shares held short 1.40M
- Nov 30, 2023: Shares held short 1.52M
- Dec 15, 2023: Shares held short 1.81M
- Dec 29, 2023: Shares held short 1.98M
- Jan 12, 2024: Shares held short 2.26M
- Jan 31, 2024: Shares held short 2.15M
- Feb 15, 2024: Shares held short 2.40M
- Feb 29, 2024: Shares held short 2.46M
- Mar 15, 2024: Shares held short 2.62M
- Mar 28, 2024: Shares held short 2.68M
- Apr 15, 2024: Shares held short 2.46M
- Apr 30, 2024: Shares held short 2.37M
- May 15, 2024: Shares held short 2.61M
- May 31, 2024: Shares held short 2.93M
- Jun 14, 2024: Shares held short 3.08M
- Jun 28, 2024: Shares held short 2.96M
- Jul 15, 2024: Shares held short 3.00M
- Jul 31, 2024: Shares held short 3.00M
- Aug 15, 2024: Shares held short 2.59M
- Aug 30, 2024: Shares held short 1.83M
- Sep 13, 2024: Shares held short 1.46M
- Sep 30, 2024: Shares held short 1.36M
- Oct 15, 2024: Shares held short 1.43M
- Oct 31, 2024: Shares held short 1.03M
- Nov 15, 2024: Shares held short 755.6K
- Nov 29, 2024: Shares held short 937.5K
- Dec 13, 2024: Shares held short 973.4K
- Dec 31, 2024: Shares held short 1.08M
- Jan 15, 2025: Shares held short 1.01M
- Jan 31, 2025: Shares held short 985.4K
- Feb 14, 2025: Shares held short 928.7K
- Feb 28, 2025: Shares held short 1.04M
- Mar 14, 2025: Shares held short 1.15M
- Mar 31, 2025: Shares held short 1.06M
- Apr 15, 2025: Shares held short 1.51M
- Apr 30, 2025: Shares held short 1.34M
- May 15, 2025: Shares held short 1.07M
- May 30, 2025: Shares held short 899.7K
- Jun 13, 2025: Shares held short 728.3K
- Jun 30, 2025: Shares held short 819.3K
- Jul 15, 2025: Shares held short 847.3K
- Jul 31, 2025: Shares held short 987.8K
- Aug 15, 2025: Shares held short 907.1K
- Aug 29, 2025: Shares held short 807.5K
- Sep 15, 2025: Shares held short 1.13M
- Sep 30, 2025: Shares held short 1.12M
- Oct 15, 2025: Shares held short 955.9K
- Oct 31, 2025: Shares held short 958.7K
- Nov 14, 2025: Shares held short 922.1K
- Nov 28, 2025: Shares held short 1.17M
- Dec 15, 2025: Shares held short 1.37M
- Dec 31, 2025: Shares held short 1.39M
- Jan 15, 2026: Shares held short 1.27M
- Jan 30, 2026: Shares held short 1.56M
- Feb 13, 2026: Shares held short 1.80M
- Feb 27, 2026: Shares held short 1.74M
- Mar 13, 2026: Shares held short 1.76M
- Mar 31, 2026: Shares held short 1.82M
- Apr 15, 2026: Shares held short 1.62M
- Apr 30, 2026: Shares held short 1.87M
- May 15, 2026: Shares held short 2.17M
- May 29, 2026: Shares held short 1.81M
- Jun 15, 2026: Shares held short 2.01M
- Jun 30, 2026: Shares held short 2.34M
- Jul 15, 2026: Shares held short 2.44M
- Jul 31, 2026: Shares held short 3.16M
- Aug 14, 2026: Shares held short 2.32M
- Aug 31, 2026: Shares held short 2.44M
- Sep 15, 2026: Shares held short 2.79M
- Sep 30, 2026: Shares held short 2.86M
- Oct 15, 2026: Shares held short 2.40M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading61.0% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 61.0% of the shares in the reported trades were short sales, against 48.0% in the 14 before.
- Last 14 sessionsOct 27, 2026 – Nov 13, 2026
- 61.0%
- The 14 beforeOct 7, 2026 – Oct 26, 2026
- 48.0%
- Change
- +13.0 pts
- Short sales a dayon average, of 327.8K shares
- 200.1K
- More than atof 3,649 US-listed companies, same days
- 86%
- Median of alleight in ten from 34.6% to 63.4%
- 50.1%
- Short sales
- Oct 7, 2026: Short sales 51%
- Oct 8, 2026: Short sales 56.3%
- Oct 9, 2026: Short sales 67.8%
- Oct 12, 2026: Short sales 72.9%
- Oct 13, 2026: Short sales 59.4%
- Oct 14, 2026: Short sales 47.4%
- Oct 15, 2026: Short sales 42.5%
- Oct 16, 2026: Short sales 47.6%
- Oct 19, 2026: Short sales 71.2%
- Oct 20, 2026: Short sales 56.5%
- Oct 21, 2026: Short sales 24.5%
- Oct 22, 2026: Short sales 48.1%
- Oct 23, 2026: Short sales 65.1%
- Oct 26, 2026: Short sales 45%
- Oct 27, 2026: Short sales 60.3%
- Oct 28, 2026: Short sales 60.7%
- Oct 29, 2026: Short sales 67%
- Oct 30, 2026: Short sales 39.5%
- Nov 2, 2026: Short sales 57.2%
- Nov 3, 2026: Short sales 63.3%
- Nov 4, 2026: Short sales 44.7%
- Nov 5, 2026: Short sales 61.5%
- Nov 6, 2026: Short sales 75%
- Nov 9, 2026: Short sales 61.3%
- Nov 10, 2026: Short sales 68.2%
- Nov 11, 2026: Short sales 67.6%
- Nov 12, 2026: Short sales 73%
- Nov 13, 2026: Short sales 78.2%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Richard C BreedenDirectorDirectly66.2K
- Daniel A CarestioPresident and CEODirectly63.6K
- John Adam ZangerleSr. VP, Gen Counsel, and Sec.Directly35.3K
- Mohsen SohiDirectorDirectly24.3K
- Cary L MajorsSVP and President, HealthcareDirectly17.4K
- Mary Clare FraserSVP & Chief HRODirectly13.7K
- Karen L BurtonSr. Vice Pres., CFODirectly13.0K
- Julia MadsenSr. VP and GM, Life SciencesDirectly12.3K
- Kenneth E KohlerSVP & GM, ASTDirectly11.3K
- Renato TamaroV.P. & Corporate TreasurerDirectly6,194
- Lindsey McGowanVP, Chf. Comp. & Quality Offc.Directly5,911
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Richard C BreedenDirector | 66.2K | – | Jun 2, 2026 | Form 4 |
| Daniel A CarestioPresident and CEO | 63.6K | – | Jun 5, 2026 | Form 4 |
| John Adam ZangerleSr. VP, Gen Counsel, and Sec. | 35.3K | – | Jun 15, 2026 | Form 4 |
| Mohsen SohiDirector | 24.3K | – | Nov 10, 2026 | Form 4 |
| Cary L MajorsSVP and President, Healthcare | 17.4K | – | Jun 2, 2026 | Form 4 |
| Mary Clare FraserSVP & Chief HRO | 13.7K | – | Jun 4, 2026 | Form 4 |
| Karen L BurtonSr. Vice Pres., CFO | 13.0K | – | Nov 11, 2026 | Form 4 |
| Julia MadsenSr. VP and GM, Life Sciences | 12.3K | – | Jun 4, 2026 | Form 4 |
| Kenneth E KohlerSVP & GM, AST | 11.3K | – | Jun 4, 2026 | Form 4 |
| Renato TamaroV.P. & Corporate Treasurer | 6,194 | – | Jun 4, 2026 | Form 4 |
| Lindsey McGowanVP, Chf. Comp. & Quality Offc. | 5,911 | – | Jun 2, 2026 | Form 4 |
A lower bound: it counts only the 11 officers and directors with a market trade since Nov 17, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- J. Adam ZangerleSenior Vice President, General Counsel, and Company Secretary of the CompanyWhat happenedAdoptedNov 19, 2025Shares16.0K
- Daniel A. CarestioPresident and Chief Executive OfficerWhat happenedAdoptedJun 6, 2024Shares62.0K
- J. Adam ZangerleSenior Vice President, General Counsel, and Company Secretary of the CompanyWhat happenedAdoptedMay 15, 2024Shares17.8K
- Michael J. TokichSenior Vice President and Chief Financial OfficerWhat happenedAdoptedMay 15, 2024Shares46.7K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| J. Adam ZangerleSenior Vice President, General Counsel, and Company Secretary of the Company | AdoptedNov 19, 2025 | Mar 15, 2027 | 16.0K | 10-Q |
| Daniel A. CarestioPresident and Chief Executive Officer | AdoptedJun 6, 2024 | 729 days | 62.0K | 10-Q |
| J. Adam ZangerleSenior Vice President, General Counsel, and Company Secretary of the Company | AdoptedMay 15, 2024 | 535 days | 17.8K | 10-Q |
| Michael J. TokichSenior Vice President and Chief Financial Officer | AdoptedMay 15, 2024 | 758 days | 46.7K | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$12M
Actually paid: $3.3M
$2.6M
Actually paid: $2.1M
$121
Peers: $107
Adjusted EBIT
$1.4B
From the proxy statement (DEF 14A) of Jun 11, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jun 30, 202610-QAmount$107M
- Mar 31, 202610-KAmount$74M
- Dec 31, 202510-QAmount$52M
- Sep 30, 202510-QAmount$99M
- Mar 31, 202510-KAmount–
- Dec 31, 202410-QAmount$100M
- Sep 30, 202410-QAmount$44M
- Jun 30, 202410-QAmount$56M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jun 30, 202610-Q | 500.0K | $214.10 | $107M | $900M | 10-Q |
| Mar 31, 202610-K | 300.0K | $245.57 | $74M | $75M | 10-K |
| Dec 31, 202510-Q | 200.0K | $259.78 | $52M | $150M | 10-Q |
| Sep 30, 202510-Q | 400.0K | $246.60 | $99M | $200M | 10-Q |
| Mar 31, 202510-K | – | – | – | $300M | 10-K |
| Dec 31, 202410-Q | 460.5K | $217.16 | $100M | $300M | 10-Q |
| Sep 30, 202410-Q | 195.2K | $224.83 | $44M | $400M | 10-Q |
| Jun 30, 202410-Q | 251.5K | $223.15 | $56M | $444M | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 7 filing(s) not shown, as the table was not read or did not agree with the cash.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it. 1 filing(s) not read, as the table is not in the usual shape.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund0.36%
- VHTVanguard Health Care Index FundWeight in the fund0.32%
- VOTVanguard Mid-Cap Growth Index FundWeight in the fund0.23%
- RSPInvesco S&P 500 Equal Weight ETFWeight in the fund0.21%
- IWSiShares Russell Mid-Cap Value ETFWeight in the fund0.20%
- VOVanguard Mid-Cap Index FundWeight in the fund0.20%
- SPHQInvesco S&P 500 Quality ETFWeight in the fund0.19%
- VOEVanguard Mid-Cap Value Index FundWeight in the fund0.18%
- IWRiShares Russell Mid-Cap ETFWeight in the fund0.15%
- GSLCGoldman Sachs ActiveBeta(R) U.S. Large Cap Equity ETFWeight in the fund0.15%
36 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 847
- Q4 2025: Managers 901
- Q1 2026: Managers 852
- Q2 2026: Managers 835
Institutional investors by quarter
The fund managers holding STE, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 835 managers held 95.29M shares, worth $20.1B. During the quarter 104 opened a position, 121 closed one, 293 added and 302 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter-2.3%
- Vanguard Capital ManagementIn the quarter+0.6%
- State StreetIn the quarter+1.6%
- Vanguard Portfolio ManagementIn the quarter+1.0%
- Morgan StanleyIn the quarter-10%
- Massachusetts Financial ServicesIn the quarter-5.2%
- Wellington Management GroupIn the quarter+22%
- Orbis Allan GrayIn the quarter+3.3%
- Geode Capital ManagementIn the quarter+1.3%
- Generation Investment ManagementIn the quarter-1.2%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 8.82M | -2.3% | $1.9B |
| Vanguard Capital Management | 6.41M | +0.6% | $1.3B |
| State Street | 5.07M | +1.6% | $1.1B |
| Vanguard Portfolio Management | 5.00M | +1.0% | $1.1B |
| Morgan Stanley | 3.95M | -10% | $832M |
| Massachusetts Financial Services | 3.80M | -5.2% | $850M |
| Wellington Management Group | 3.50M | +22% | $738M |
| Orbis Allan Gray | 2.68M | +3.3% | $564M |
| Geode Capital Management | 2.62M | +1.3% | $549M |
| Generation Investment Management | 2.28M | -1.2% | $480M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do STERIS's filings show?
Who buys and sells is one part of STERIS's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have STE's insiders bought or sold?
From Jun 3, 2026 to Nov 12, 2026 STERIS's insiders bought 0 and sold $5.3M of shares on the market. 24% of the sales were under set 10b5-1 plans.
Which well-known managers hold STE?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $286M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.